The tumor specimens obtained from these individuals were expected to demonstrate positive immunological reactions in relation to PD-1/PD-L1 inhibitors, CTLA4 inhibitors, or a combination of both therapeutic interventions. The gene discussed is CTLA4; the disease is neoplasm.